CYXO BTA Stock Overview
A clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cyxone AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.038 |
| 52 Week High | SEK 0.042 |
| 52 Week Low | SEK 0.038 |
| Beta | 0.38 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYXO BTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 1.5% |
| 1Y | n/a | 22.9% | 22.2% |
Return vs Industry: Insufficient data to determine how CYXO BTA performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how CYXO BTA performed against the Swedish Market.
Price Volatility
| CYXO BTA volatility | |
|---|---|
| CYXO BTA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CYXO BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CYXO BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Kjell Stenberg | www.cyxone.com |
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ) Fundamentals Summary
| CYXO BTA fundamental statistics | |
|---|---|
| Market cap | SEK 8.85m |
| Earnings (TTM) | -SEK 22.37m |
| Revenue (TTM) | SEK 4.86m |
1.8x
P/S Ratio-0.4x
P/E RatioIs CYXO BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYXO BTA income statement (TTM) | |
|---|---|
| Revenue | SEK 4.86m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 4.86m |
| Other Expenses | SEK 27.22m |
| Earnings | -SEK 22.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -460.40% |
| Debt/Equity Ratio | 0% |
How did CYXO BTA perform over the long term?
See historical performance and comparison